Study Data from Konkuk University Update Knowledge of Small Interference RNAs (siRNAs) (Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer)
By a News Reporter-Staff News Editor at Biotech Week -- A new study on Small Interference RNAs (siRNAs) is now available. According to news reporting from Seoul, South Korea, by NewsRx journalists, research stated, "The purpose of this study was to investigate the antitumor effects of a combination of metronomic doses of a novel delivery vehicle, PLGA-PRINT nanoparticles containing docetaxel, and antiangiogenic mEZH2 siRNA incorporated into chitosan nanoparticles. In vivo dose-finding studies and therapeutic experiments were conducted in well-established orthotopic mouse models of epithelial ovarian cancer."
The news correspondents obtained a quote from the research from Konkuk University, "Antitumor effects were determined on the basis of reduction in mean tumor weight and number of metastatic tumor nodules in the animals. The tumor tissues from these in vivo studies were stained to evaluate the proliferation index (Ki67), apoptosis index (cleaved caspase 3), and microvessel density (CD31). The lowest dose of metronomic regimen (0.5 mg/kg) resulted in significant reduction in tumor growth. The combination of PLGA-PRINT-docetaxel and CH-mEZH2 siRNA showed significant antitumor effects in the HeyA8 and SKOV3ip1 tumor models (P < 0.05). Individual as well as combination therapies showed significant antiangiogenic, antiproliferative, and proapoptotic effects, and combination therapy had additive effects."
According to the news reporters, the research concluded: "Metronomic delivery of PLGA-PRINT-docetaxel combined with CH-mEZH2siRNA has significant antitumor activity in preclinical models of ovarian cancer."
For more information on this research see: Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer. Molecular Cancer Therapeutics, 2014;13(7):1750-1757. Molecular Cancer Therapeutics can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Molecular Cancer Therapeutics - mct.aacrjournals.org/)
Our news journalists report that additional information may be obtained by contacting K.M. Gharpure, Konkuk University, Sch Med, Dept. of Immunol, Seoul, South Korea. Additional authors for this research include K.S. Chu, C.J. Bowerman, T. Miyake, S. Pradeep, S.L. Mangala, H.D. Han, R. Rupaimoole, G.N. Armaiz-Pena, T.B. Rahhal, S.Y. Wu, J.C. Luft, M.E. Napier, G. Lopez-Berestein, J.M. DeSimone and A.K. Sood (see also Small Interference RNAs (siRNAs)).
Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Seoul, Drugs, Cancer, Therapy, Genetics, Oncology, Docetaxel, South Korea, Nanoparticle, Nanotechnology, Mitotic Inhibitors, Emerging Technologies, Small Interference RNAs (siRNAs)
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC